Zymeworks

  • Biotech or pharma, therapeutic R&D

Zymeworks (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. We are focused on moving novel therapeutics into the clinic in 2024 and 2025, including ZW191, a best-in-class FRα-targeting ADC now in first-in-human studies, and ZW251, a GPC3-targeting ADC planned for 2025—both leveraging our proprietary TOPO1i payload, ZD06519. We are also advancing next-generation multispecific antibodies, including ZW171, a 2+1 mesothelin-directed T-cell engager that entered the clinic in 2024, and ZW209, a preclinical DLL3-targeting trispecific TCE incorporating CD28 co-stimulation.

Address

Vancouver
BC
Canada

Website

http://www.zymeworks.com

Contact Exhibitor


Loading
View all Partnering Companies

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS